Glaucoma Market Forecast 2025-2034: Analysing Major Trends, Opportunities, and Growth Drivers

Which drivers are expected to have the greatest impact on the over the glaucoma market's growth?
The increasing instances of long-term eye disorders are anticipated to drive the growth of the glaucoma market. These chronic conditions often lead to enduring visual impairment, discomfort and necessitate continuous treatment or management. Factors such as aging population, increased time spent on screens, lifestyle choices, and greater occurrence of diseases such as diabetes and hypertension have contributed to the surge in these eye conditions. Treatment for glaucoma is necessary for these conditions to reduce intraocular pressure, avert further optic nerve damage, and retain vision, since unchecked glaucoma can result in irreversible blindness. As reported by the National Health Service (NHS) of the UK, a publicly funded healthcare system, over 2 million people in the UK had sight loss in December 2024. Furthermore, the count of people experiencing sight loss is estimated to rise by 27%, hitting approximately 2.8 million by 2035. Hence, the escalating frequency of chronic eye conditions is fuelling the glaucoma market.

Get Your Glaucoma Market Report Here:
https://www.thebusinessresearchcompany.com/report/glaucoma-global-market-report

What is the future CAGR of the glaucoma market, and how will it impact industry expansion?
In the past few years, the size of the glaucoma market has seen significant growth. It is projected to increase from $7.76 billion in 2024 to an estimated $8.22 billion in 2025, with a compound annual growth rate (CAGR) of 5.9%. Growing health consciousness towards eye care, rising healthcare expenditures, increasing utilization of telemedicine for eye care services, the expansion of healthcare infrastructure, and government initiatives in healthcare have all contributed to the growth of the market in the historical period.

The glaucoma market is anticipated to experience significant expansion in the coming years. The market value is projected to reach $10.20 billion by 2029, with an estimated compound annual growth rate (CAGR) of 5.5%. The growth during the projected period is mainly due to an aging population, increasing glaucoma cases, a growing need for less invasive surgical procedures, and a rising prevalence of diabetes and hypertension. Major trends expected during this period encompass advances in diagnostic technology, the introduction of new drug therapies, technological breakthroughs in surgical instruments, the availability of combined therapies, and the implementation of robotic surgeries.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20820&type=smp

What new trends are reshaping the glaucoma market and its opportunities?
Dominant enterprises in the glaucoma sector are concentrating on the creation of unique therapies such as Rho-kinase (ROCK) inhibitors. These inhibitors offer a dual-action solution by lessening intraocular pressure through the augmentation of aqueous humor outflow and relaxation of trabecular meshwork cells, proving useful for glaucoma treatment. ROCK inhibitors belong to a drug category designed to suppress Rho-kinase enzyme functions involved in cell contraction, thereby providing relief in glaucoma cases through intraocular pressure reduction. For example, Roclanda, a fixed-dose combination of latanoprost and netarsudil (a newly introduced ROCK inhibitor) was launched in the UK by Japan's Santen Pharmaceutical Co. Ltd. in July 2023. Roclanda targets trabecular meshwork dysfunction and efficiently brings down intraocular pressure. It is recommended for adults with either primary open-angle glaucoma or ocular hypertension whose IOP reduction has been inadequate with monotherapy of a prostaglandin or netarsudil. European introduction of Roclanda signifies the first new glaucoma drug classification in a quarter of a century, indicating a significant advancement in treatment methodology. By combining netarsudil and latanoprost, Roclanda boosts outflow via trabecular (traditional) and uveoscleral (non-traditional) passages, thus offering an all-inclusive solution for raised IOP management.

Which key market segments comprise the glaucoma market and drive its revenue growth?
The glaucoma market covered in this report is segmented -

1) By Disease Type: Open Angle Glaucoma, Angle Closure Glaucoma, Other Disease Types
2) By Diagnosis: Tonometry, Ophthalmoscopy, Perimetry, Gonioscopy
3) By Drug Class: Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Combination Drugs, Other Drug Classes
4) By Administration: Oral, Injections, Intravitreal, Other Administrations
5) By End-User: Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers

Subsegments:
1) By Open Angle Glaucoma: Primary Open Angle Glaucoma (POAG), Secondary Open Angle Glaucoma
2) By Angle Closure Glaucoma: Primary Angle Closure Glaucoma, Secondary Angle Closure Glaucoma
3) By Other Disease Types: Normal-Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma, Congenital Glaucoma

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20820

What regions are at the forefront of glaucoma market expansion?
North America was the largest region in the glaucoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glaucoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the leading players fueling growth in the glaucoma market?
Major companies operating in the glaucoma market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Bausch & Lomb Corp., Carl Zeiss Meditec, Santen Pharmaceuticals Co. Ltd., Topcon Corporation, Thea Laboratoires, Corza Ophthalmology, Lumenis Ltd., Alcon Inc., Viva BioInnovator, Glaukos Corporation, Iridex Corporation, Nova Eye Medical Ltd., Renova Life Sciences Private Limited, Qlaris Bio Inc., PolyActiva Pty Ltd., Nidek Co. Ltd., Haag-Streit AG

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=20820&type=smp

What Is Covered In The Glaucoma Global Market Report?

•Market Size Forecast: Examine the glaucoma market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the glaucoma market for a structured understanding.
•Key Players Overview: Analyze major players in the glaucoma market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the glaucoma market.
•Segment Contributions: Evaluate how different segments drive overall growth in the glaucoma market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the glaucoma market.
•Industry Challenges: Identify potential risks and obstacles affecting the glaucoma market.
•Competitive Landscape: Review strategic developments in the glaucoma market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.